IGF-1 LR3 100 mcg
Educational recon guide for a 100 mcg IGF-1 LR3 research vial and microgram daily unit mapping. Research use only — high-caution growth-factor product.
Vial size
Same research phases — calculator defaults and unit math match the selected vial strength.
Vial
100 mcg
Your BAC water
1 mL
Concentration
0.10 mg/mL
Per unit
~1.0 mcg
Frequency
Once daily (sometimes split) subcutaneous for short multi-week courses, then time off
Route
Subcutaneous (some community write-ups also discuss IM near trained muscle)
Live reconstitution calculator
Defaults match this guide (100 mcg + 1 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
This guide uses microgram-scale research doses — quick picks are in mcg (100 mcg = 0.1 mg).
Quick select (mcg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
20 units
Volume
0.200 mL
Doses per vial
5
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 20 u
Fill one 30-unit U-100 syringe to about 20 units (0.200 mL).
Research cycle phases
Units and volumes recompute from your Step 1 concentration (1 mL BAC → 0.10 mg/mL · 1.0 mcg/unit). Doses below are once daily during the course — not weekly.
Standard course
Secondary educational tables commonly discuss ~20–50 mcg once daily for about 4–6 weeks, then time off. Higher amounts increase hypoglycemia and IGF-pathway risk discussions. Not a beginner recovery peptide.
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Days 1–14 (intro) | 20 mcg0.02 mg | 20 u | 0.20 mL20 mcg daily — common educational start |
| Days 15–42 (standard) | 40 mcg0.04 mg | 40 u | 0.40 mL40 mcg daily — mid common research-community range |
Alternate / higher courses
Shorter or higher daily courses discussed in research communities — not a clinical recommendation
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Higher educational · 50 mcg × 28 days | 50 mcg0.05 mg | 50 u | 0.50 mL50 mcg daily — upper end of many conservative tables |
| Higher educational · 80 mcg × 21 days | 80 mcg0.08 mg | 80 u | 0.80 mLAbove many conservative charts — educational only; hypoglycemia risk rises |
Supplies planner
Using the guide’s phase ladder (20 mcg → 40 mcg per injection (phase ladder)) over a 42-day course. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
1 mL · 0.10 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
42-day course
IGF-1 LR3 0.1 mg vials
14 vials
~1.4 mg mg total peptide over this 42-day course at 20 mcg → 40 mcg per injection (phase ladder). Each vial holds 0.1 mg.
Bacteriostatic water
5 × 3 mL or 2 × 10 mL
1 mL BAC per vial × 14 vials = 14.0 mL total. Buy as 5× 3 mL bottles or 2× 10 mL bottles (whichever you stock).
U-100 insulin syringes (100-unit)
42+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~112 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 100 mcg IGF-1 LR3 vial and bacteriostatic water to reach room temperature.
- Draw 1.0 mL bacteriostatic water (default). Some researchers use acetic acid diluent protocols for IGF products — follow your validated lab method.
- Inject diluent slowly down the inner wall — avoid foaming.
- Gently swirl until clear. Do not shake hard.
- Label with recon date and concentration.
- Refrigerate at 2–8 °C (35–46 °F). Prefer finishing within the short course window.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·IGF-1 LR3 is a long-acting IGF-1 analogue discussed in performance research communities.
- ·Calculator: 0.02 mg = 20 mcg; 0.05 mg = 50 mcg.
- ·Short courses with time off are the usual educational framing — not year-round daily use.
- ·Research use only.
Research context & considerations
Long R3 IGF-1 is engineered for extended activity vs native IGF-1. It is not an approved bodybuilding or anti-aging drug; hypoglycemia and theoretical growth/malignancy pathway concerns are central risk themes.
- ·Hypoglycemia / blood-sugar effects.
- ·Theoretical promotion of cell growth — active malignancy is a high-caution context.
- ·Injection-site and systemic side effects vary.
- ·Not FDA-approved for research-vial consumer use.
- ·Pregnancy out of scope.
Catalog match
IGF-1 LR3 (IG01)
100mcg x 10 vials · from $20